Design, Synthesis, and Antitumor Activities of Novel Coumarin-Based Histone Deacetylase Inhibitors.

Sichang Yan, Jie Chang, Dongyu Lei, Xiangyang Lv, Yanzhuo Li, Yue Zhuo, Lu Jin, Le Pan

Abstract read

In one paragraph

Article in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sichang YanCollege of Chemistry and Chemical Engineering, Xinjiang Agricultural University, Urumqi 830052, China.

Jie ChangCollege of Chemistry and Chemical Engineering, Xinjiang Agricultural University, Urumqi 830052, China.

Dongyu LeiDepartment of Physiology, Preclinical School, Xinjiang Medical University, Urumqi 830011, China.

Xiangyang LvCollege of Chemistry and Chemical Engineering, Xinjiang Agricultural University, Urumqi 830052, China.

Yanzhuo LiCollege of Chemistry and Chemical Engineering, Xinjiang Agricultural University, Urumqi 830052, China.

Yue ZhuoCollege of Chemistry and Chemical Engineering, Xinjiang Agricultural University, Urumqi 830052, China.

Lu JinCollege of Chemistry and Chemical Engineering, Xinjiang Agricultural University, Urumqi 830052, China.ORCID 0000-0001-6513-6206

Le PanCollege of Chemistry and Chemical Engineering, Xinjiang Agricultural University, Urumqi 830052, China.

Funding

National Natural Science Foundation of China NO. 31960547Tianshan Innovation Team Foundation of Xinjiang NO. 2024D14008

6 · The paper itself

Abstract

Histone deacetylases (HDACs) are important epigenetic regulatory enzymes contributing to cancer proliferation, which could be critical targets in cancer therapy. The structural similarities of the existing HDAC inhibitors have resulted in an increase in the drug resistance. In this study, coumarin was employed as the core scaffold for structural derivatisation to develop a novel class of HDAC inhibitors based on computer-aided design (CADD). Their anti-tumor activity was evaluated against esophageal squamous cell lines. The results showed that most compounds exhibited potent anti-proliferative activity against KYSE70 and KYSE150. Among them, compound

Indexed as

Antineoplastic AgentsCoumarinsDrug DesignHistone Deacetylase InhibitorsCell Line, TumorCell ProliferationHistone DeacetylasesHumansMolecular Docking SimulationAntineoplastic AgentscoumarinCoumarinsHistone Deacetylase InhibitorsHistone Deacetylasesanti-tumor activitycoumarin derivativesdesign and synthesisHDAC inhibitorstranscriptome sequencing

Identifiers

PMID42509772

DOI10.3390/biom16070978

PMCPMC13406824

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.